OTCMKTS:ATMS

Artemis Therapeutics (ATMS) Stock Forecast, Price & News

$0.51

+0.21 (+70.00%)

(As of 05/18/2023 ET)

Compare

Today's Range: $0.33
▼
$0.51
50-Day Range: $0.17
▼
$1.11
52-Week Range: $0.11
▼
$5.00

Volume: 200 shs
Average Volume: 3,007 shs
Market Capitalization: $57.14 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile Chart Competitors Earnings Financials Insider Trades Headlines SEC Filings Short Interest

About Artemis Therapeutics (OTCMKTS:ATMS) Stock

Artemis Therapeutics, Inc. is a biopharmaceutical company. It develops new treatments for serious and life-threatening infections. It Includes cytomegalovirus and malaria. The company was founded on April 22, 1997 and was headquartered in New York, NY.

Receive ATMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artemis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATMS Stock News Headlines

May 8, 2023 | msn.com

Marker Therapeutics gets new chief medical officer

April 27, 2023 | finance.yahoo.com

ARTEMIS, a soccer-playing humanoid robot, is ready for the pitch

May 18, 2023 | Behind the Markets (Ad)

"Chilling War Games Show US Forces Crushed" – FOX NEWS

=== BREAKING === "Chilling War Games Show US Forces Crushed" - FOX NEWS After losing to China in repeated war games, U.S. military to spend billions on new "living missile" for armed forces. Investors stand to reap 35,960% on shares of small defense contractor that makes powerful new weapon. Get the name of the stock here >>>

April 23, 2023 | usatoday.com

SpaceX Starship, larger and more powerful than Artemis SLS, explodes on first launch attempt

March 18, 2023 | theguardian.com

Nasa reveals new spacesuit for Artemis moon landing

January 7, 2023 | finance.yahoo.com

Artemis Therapeutics Inc. (ATMS)

November 16, 2022 | cbsnews.com

NASA managers order review of hurricane-damaged insulation before moon rocket launch

November 10, 2022 | msn.com

NASA’s Artemis I suffers ‘very minor’ damage from Nicole

May 18, 2023 | Behind the Markets (Ad)

"Chilling War Games Show US Forces Crushed" – FOX NEWS

October 10, 2022 | reuters.com

Artemis Therapeutics Inc

September 27, 2022 | yahoo.com

Artemis I leaves launch pad ahead of Hurricane Ian

August 18, 2022 | news.yahoo.com

Nasa’s Artemis 1 moon mission explained

August 6, 2022 | yahoo.com

NASA's Artemis I moon mission includes educational, cultural, and commemorative mementos

June 2, 2022 | finance.yahoo.com

NASA Selects New Instruments for Priority Artemis Science on Moon

May 6, 2022 | msn.com

Washington plays key role In NASA's Artemis missions

March 25, 2022 | yahoo.com

Cannes Chooses Former WarnerMedia Exec Iris Knobloch To Succeed Pierre Lescure As President

July 8, 2021 | in.finance.yahoo.com

Eureka Therapeutics Announces New GPRC5D License Agreement with Sanofi to Target Multiple Myeloma

April 30, 2021 | in.finance.yahoo.com

LendingPoint Recognized by Atlanta Business Chronicle’s Pacesetter Award for Fourth Consecutive Year

April 30, 2021 | ca.finance.yahoo.com

Caution: Most Stocks Fail! Do This to Build a Winning Stock Portfolio

April 29, 2021 | au.finance.yahoo.com

Essex Communities Announces New Leadership Structure to Accommodate Rapid Growth

April 29, 2021 | au.finance.yahoo.com

‘The Falcon and Winter Soldier’ fails to pay off on its initial promise

March 25, 2021 | yahoo.com

Another piebald deer stops by a trail camera for a photo

March 25, 2021 | yahoo.com

Mum selling her possessions to fund £35K surgery before rare condition leaves her paralysed

November 18, 2020 | seekingalpha.com

Lineage: OPC1, VAC2, And OpRegen Are Making Progress With Several 2020 Catalysts, 48% Upside

January 21, 2019 | finance.yahoo.com

Artemis Therapeutics Announces Additional Patent Issuance For Artemisone For The Treatment Of Viral Infections

January 21, 2019 | finance.yahoo.com

New Data Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication

January 21, 2019 | finance.yahoo.com

Data Presented At The 31st International Conference For Antiviral Research Demonstrate Artemis Therapeutics' Artemisone May Be An Effective Inhibitor Of Human CMV Replication

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ATMS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artemis Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATMS Company Calendar

Today: 5/18/2023
Next Earnings (Estimated): 5/22/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Miscellaneous chemical products
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ATMS
CUSIP: N/A
CIK: 1062128
Web: www.artemis-therapeutics.com
Phone: (646) 233-1454
Fax: 800-253-5177
Employees: 1
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-1,360,000.00
Net Margins: N/A
Pretax Margin: -435.69%
Return on Equity: N/A
Return on Assets: -524.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.14
Quick Ratio: 0.10

Sales & Book Value

Annual Sales: $310,000.00
Price / Sales: 184.31
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.01) per share
Price / Book: -51.00

Miscellaneous

Outstanding Shares: 112,030,000
Free Float: 103,687,000
Market Cap: $57.14 million
Optionable: Not Optionable
Beta: -1.92

Key Executives

Shimon Citron
Chief Executive Officer & Director

Haim Tabak
Chief Operating Officer

David Dana
Chief Financial Officer

Dana Wolf
Chief Medical Officer

Key Competitors

View All Competitors

ATMS Stock - Frequently Asked Questions

How have ATMS shares performed in 2023?: Artemis Therapeutics' stock was trading at $1.16 at the beginning of 2023. Since then, ATMS shares have decreased by 56.0% and is now trading at $0.51.
View the best growth stocks for 2023 here.
Are investors shorting Artemis Therapeutics?: Artemis Therapeutics saw a drop in short interest in April. As of April 15th, there was short interest totaling 100 shares, a drop of 83.3% from the March 31st total of 600 shares. Based on an average daily trading volume, of 4,000 shares, the days-to-cover ratio is presently 0.0 days.
View Artemis Therapeutics' Short Interest.
When is Artemis Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 22nd 2023.
View our ATMS earnings forecast.
What is Artemis Therapeutics' stock symbol?: Artemis Therapeutics trades on the OTCMKTS under the ticker symbol "ATMS."

How do I buy shares of Artemis Therapeutics?: Shares of ATMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Artemis Therapeutics' stock price today?: One share of ATMS stock can currently be purchased for approximately $0.51.
How much money does Artemis Therapeutics make?: Artemis Therapeutics (OTCMKTS:ATMS) has a market capitalization of $57.14 million and generates $310,000.00 in revenue each year.
How can I contact Artemis Therapeutics?: Artemis Therapeutics' mailing address is 18 EAST 16TH STREET SUITE 307, NEW YORK NY, 10003. The official website for the company is www.artemis-therapeutics.com. The company can be reached via phone at (646) 233-1454, via email at ir@artemis-therapeutics.com, or via fax at 800-253-5177.

This page (OTCMKTS:ATMS) was last updated on 5/18/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Artemis Therapeutics (ATMS) Stock Forecast, Price & News

About Artemis Therapeutics (OTCMKTS:ATMS) Stock

ATMS Stock News Headlines

ATMS Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

ATMS Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info